EMA Authorised: Zypadhera (olanzapine pamoate) — CHEPLAPHARM Registration GmbH

View source ↗

Summary

EMA authorised Zypadhera, an olanzapine pamoate long-acting injectable, for schizophrenia, for CHEPLAPHARM Registration GmbH, decision date 13 November 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Zypadhera (olanzapine pamoate)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia. MAH: CHEPLAPHARM Registration GmbH. Decision date: 13/11/2025